Boston, MA 02/13/2014 (wallstreetpr) – US-origin Advanced Micro Devices, Inc. (NYSE:AMD) which has cornered the niche advanced electronic device market with its bleeding-edge technology platforms, appears to be turning the corner on the next technology level. In close competition with long-time same niche player INTEL, AMD has its work cut out.
Transforming technology, which both of these are adept, while now become more niche! As users move from PC-use to hand held smart device and wearable technology, Advanced Micro Devices, Inc. (NYSE:AMD) has bolstered its pipeline technology on gamin g, graphics as well as micro servers. Intel will remain more specific and will continue to bring higher density of features on its Baytrail chips.
Narrow Earnings loss
Meanwhile, Alpha Natural Resources, Inc. (NYSE:ANR) has reported a better fourth quarter earnings loss, in comparison to expected higher loss. Eventually the declared revenue was $1.1 billion, though down by over 29.5% in comparison to previous year. These revenues were much higher than expected by over $80 million. It beat EPS for fourth quarter by $0.09.
Alpha Natural Resources, Inc. (NYSE:ANR) reported drop in coal sale by 20.6 million tons from the previous 25.9 million. The move by most consumers to the thermal coal segment has driven the sale of coal in this segment. However, metallurgical coal sale has been disappointing as steelmaking units, especially in China are in the process of realigning with regulatory requirements and can no longer compromise on poor quality, pollutant-emitting coal.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), the makers of cancer-killing drug has mixed performance on the stock market. It new drug- Iclusig- which is used in the treatment of refractory leukemia. Ariad had previously in October 2013, withdrawn Iclusig, following a spate of reports of cardiovascular issues. However, ARIA followed a fast-track workforce-resize of over 40% to retrench cash and move Iclusig before FDA. The concentrated efforts before FDA along with active participation of Cancer advocacy groups finally led to the FDA re-approval to sell Iclusig in the markets by Dec of 2013. Since then the stock of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) has traded steadily at about $7.
